EU/3/04/220

Table of contents

About

On 2 September 2004, orphan designation (EU/3/04/220) was granted by the European Commission to Oncoscience AG, Germany, for anti epidermal growth factor receptor antibody h-R3 (cimazumab) for the treatment of glioma.

The sponsorship was transferred to Oncoscience GmbH, Germany, in September 2018.

Key facts

Active substance
Anti epidermal growth factor receptor antibody h-R3
Disease / condition
Treatment of glioma
Date of first decision
02/09/2004
Outcome
Positive
EU designation number
EU/3/04/220

Sponsor's contact details

Oncoscience GmbH
Osterbrooksweg 59
22869 Schenefeld
Germany
Tel. +49 40 300 97 990
E-mail: info@oncoscience.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating